2023-506429-13-00RecruitingPhase 3
An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis
F. Hoffmann-La Roche AG46 sites in 7 countries520 target enrollmentStarted: March 18, 2024Last updated:
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- F. Hoffmann-La Roche AG
- Enrollment
- 520
- Locations
- 46
- Primary Endpoint
- 1. Proportion of patients with no evidence of progression (NEP) sustained for at least 24 weeks
Study Overview
Brief Summary
To evaluate the effectiveness of ocrelizumab treatment in patients with PMS disease course
Study Design
- Allocation
- Not Applicable
- Primary Purpose
- An Open-Label, single-arm 4-year study to evaluate Ocrelizumab in patients with progressive MS
- Masking
- None
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Have a definite diagnosis of PMS (as per the revised McDonald 2010 criteria for PPMS or Lublin et al. 2014 criteria for PMS)
- •EDSS (Expanded Disability Status Scale) </ =6.5 at screening
- •Have a documented evidence of disability progression independent of relapse at any point over the 2 years prior to the screening visit. In case relapse(s) have occurred in the last 2 years, disability progression will have to be considered as independent of relapse activity as per treating physician's judgment
- •Fulfill at least one of the 21 criteria assessing the evidence of disability progression independent of relapse activity in the last 2 years using the pre-baseline disability progression rating system checklist
- •Have experience of having used a smartphone and connecting a smartphone to Wi-Fi network providers
- •For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods during the treatment period and for at least 6 months, or longer if the local label is more stringent after the last dose of study drug
Exclusion Criteria
- •Relapsing-remitting multiple sclerosis (RRMS) at screening
- •Inability to complete an MRI
- •Gadolinium (Gd) intolerance
- •Known presence of other neurological disorders
- •Positive screening tests for hepatitis B
- •Previous treatment with B-cell targeted therapies (i.e., atacicept, tabalumab, belimumab, ofatumumab, or obinutuzumab). Note: previous treatment with rituximab is allowed as long as the last dose was administered more than 6 months before the ocrelizumab infusion AND if discontinuation was due to adverse events or
Outcomes
Primary Outcomes
1. Proportion of patients with no evidence of progression (NEP) sustained for at least 24 weeks
1. Proportion of patients with no evidence of progression (NEP) sustained for at least 24 weeks
2. Proportion of patients with NEP and no active disease (NEPAD) sustained for at least 24 weeks
2. Proportion of patients with NEP and no active disease (NEPAD) sustained for at least 24 weeks
Secondary Outcomes
- 1. Change from baseline in cognitive function as measured by the Symbol Digit Modalities Test (SDMT) and the Brief Visuospatial Memory Test – Revised (BVMT-R)
- 2. Change from baseline in the patient-reported outcomes including Multiple Sclerosis Impact Scale -29, Multiple Sclerosis Walking scale -12 items, ABILHAND-56 Questionnaire, Fatigue Scale for Motor and Cognitive (FSMC) function, SymptoMScreen, 88-item Multiple Sclerosis Spasticity Scale, Numerical Pain Rating Scale, Patient Global Impression of Severity (PGIS) for upper limb, lower limb and cognitive functions
- 3. Mean change from baseline in the EDSS score over the course of the study
- 4. Time to onset of first confirmed disability progression (as measured by EDSS) sustained for at least 24 and 48 weeks
- 5. Time to onset of first >=20% increase in timed 25-foot walk test sustained for at least 24 weeks
- 6. Time to onset of first >=20% increase in 9-hole peg test sustained for at least 24 weeks
- 7. Proportion of patients with NEP
- 8. Proportion of patients with NEPAD
- 9. Proportion of patients with confirmed disability improvement (CDI) sustained for at least 24 weeks
- 10. Change in the following MRI volumetric measures: whole brain volume, cerebral white matter volume change, cortical gray matter volume, deep grey matter volume, thalamic volumes, whole and regional cerebellar volume
- 11. Change in the following lesion and tissue integrity parameters: - Number of new/enlarging T2 lesions and total T2 lesion volume - Number of T1 Gd+ lesions and total volume - Number of T1 lesions and total volume - Gd-enhancing fluid-attenuated inversion-recovery (FLAIR) meningeal lesions
- 12. Rate and nature of adverse events
- 13. Changes in clinical laboratory results
- 14. Rates of study treatment discontinuation due to adverse events
- 15. Change in the number of falls and near-falls
Investigators
Trial Information System - TISL
Scientific
F. Hoffmann-La Roche AG
Study Sites (46)
Loading locations...
Similar Trials
Completed
Phase 3
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)Multiple Sclerosis, Relapsing-RemittingNCT02637856Genentech, Inc.608
Completed
Phase 3
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)Multiple SclerosisNCT03599245Hoffmann-La Roche1,055
Unknown
Not Applicable
The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis PatientsMultiple Sclerosis RelapseNCT04902690IRCCS National Neurological Institute "C. Mondino" Foundation21
Terminated
Phase 3
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate TherapyRheumatoid ArthritisNCT00673920Genentech, Inc.314
Active, not recruiting
Phase 2
A Study of TCD601 in the Induction of Tolerance in de Novo Liver TransplantationLiver TransplantationNCT06019507ITB-Med LLC12